Exact Mass: 516.2240360000001
Exact Mass Matches: 516.2240360000001
Found 241 metabolites which its exact mass value is equals to given mass value 516.2240360000001
,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Ispinesib
C30H33ClN4O2 (516.2291908000001)
C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C273 - Antimitotic Agent
Perindoprilat glucuronide
Perindoprilat glucuronide is a metabolite of perindopril. Perindopril, or perindopril arginine, (trade names include Coversyl and Aceon) is a long-acting ACE inhibitor. Perindopril is used to treat high blood pressure, heart failure or stable coronary artery disease. It is also available in a generic form, perindopril erbumine. (Wikipedia)
1-(3-Methylphenyl)-3-[(3R)-1-[2-(2-methylphenyl)-2-oxoethyl]-2-oxo-5-phenyl-3H-1,4-benzodiazepin-3-yl]urea
Ispinesib
C30H33ClN4O2 (516.2291908000001)
Euchrenone b11
5-hydroxy-6-(4-cinnamoyl-3-methyl-1-oxobutyl)-4-n-propyl-2,2-dimethyl-2H,6H-benzo[1.2-b:3,4-b]-dipyran-2-one|7-hydroxy-8-(4-cinnamoyl-3-methyl-1-oxobutyl)-4-n-propyl-2,2-dimethyl-2H,6H-benzo[1.2-b:3,4-b]-dipyran-2-one
5-Hydroxy-8,8-dimethyl-10-(3-methyl-2-butenyl)-3-(2,2-dimethyl-5-methoxy-8-hydroxy-2H-1-benzopyran-6-yl)-4H,8H-benzo[1,2-b:5,4-b]dipyran-4-one
6-O-(3,4-dimethoxybenzoyl)crescentin IV 3-O-beta-D-glucopyranoside
10-methoxy-N(1)-methylburnamine-17-O-benzoate|10-methoxy-N1-methylburnamine-17-O-benzoate
Ala Thr Tyr Tyr
Ala Tyr Thr Tyr
Ala Tyr Tyr Thr
Asp Phe His Val
Asp Phe Val His
Asp His Phe Val
Asp His Val Phe
Asp Val Phe His
Asp Val His Phe
Phe Asp His Val
Phe Asp Val His
Phe His Asp Val
Phe His Val Asp
Phe Ser Thr Tyr
Phe Ser Tyr Thr
Phe Thr Ser Tyr
Phe Thr Tyr Ser
Phe Val Asp His
Phe Val His Asp
Phe Tyr Ser Thr
Phe Tyr Thr Ser
His Asp Phe Val
His Asp Val Phe
His Phe Asp Val
His Phe Val Asp
His His His Ser
C21H28N10O6 (516.2193188000001)
His His Ser His
C21H28N10O6 (516.2193188000001)
His Met Met Val
His Met Val Met
His Pro Thr Tyr
His Pro Tyr Thr
His Ser His His
C21H28N10O6 (516.2193188000001)
His Thr Pro Tyr
His Thr Tyr Pro
His Val Asp Phe
His Val Phe Asp
His Val Met Met
His Tyr Pro Thr
His Tyr Thr Pro
Met His Met Val
Met His Val Met
Met Met His Val
Met Met Val His
Met Val His Met
Met Val Met His
Asn Pro Thr Trp
Asn Pro Trp Thr
Asn Gln Gln Gln
Asn Thr Pro Trp
Asn Thr Trp Pro
Asn Trp Pro Thr
Asn Trp Thr Pro
Pro His Thr Tyr
Pro His Tyr Thr
Pro Asn Thr Trp
Pro Asn Trp Thr
Pro Gln Ser Trp
Pro Gln Trp Ser
Pro Ser Gln Trp
Pro Ser Trp Gln
Pro Thr His Tyr
Pro Thr Asn Trp
Pro Thr Trp Asn
Pro Thr Tyr His
Pro Trp Asn Thr
Pro Trp Gln Ser
Pro Trp Ser Gln
Pro Trp Thr Asn
Pro Tyr His Thr
Pro Tyr Thr His
Gln Asn Gln Gln
Gln Pro Ser Trp
Gln Pro Trp Ser
Gln Gln Asn Gln
Gln Gln Gln Asn
Gln Ser Pro Trp
Gln Ser Trp Pro
Gln Trp Pro Ser
Gln Trp Ser Pro
Ser Phe Thr Tyr
Ser Phe Tyr Thr
Ser His His His
C21H28N10O6 (516.2193188000001)
Ser Pro Gln Trp
Ser Pro Trp Gln
Ser Gln Pro Trp
Ser Gln Trp Pro
Ser Thr Phe Tyr
Ser Thr Tyr Phe
Ser Trp Pro Gln
Ser Trp Gln Pro
Ser Tyr Phe Thr
Ser Tyr Thr Phe
Thr Ala Tyr Tyr
Thr Phe Ser Tyr
Thr Phe Tyr Ser
Thr His Pro Tyr
Thr His Tyr Pro
Thr Asn Pro Trp
Thr Asn Trp Pro
Thr Pro His Tyr
Thr Pro Asn Trp
Thr Pro Trp Asn
Thr Pro Tyr His
Thr Ser Phe Tyr
Thr Ser Tyr Phe
Thr Trp Asn Pro
Thr Trp Pro Asn
Thr Tyr Ala Tyr
Thr Tyr Phe Ser
Thr Tyr His Pro
Thr Tyr Pro His
Thr Tyr Ser Phe
Thr Tyr Tyr Ala
Val Asp Phe His
Val Asp His Phe
Val Phe Asp His
Val Phe His Asp
Val His Asp Phe
Val His Phe Asp
Val His Met Met
Val Met His Met
Val Met Met His
Trp Asn Pro Thr
Trp Asn Thr Pro
Trp Pro Asn Thr
Trp Pro Gln Ser
Trp Pro Ser Gln
Trp Pro Thr Asn
Trp Gln Pro Ser
Trp Gln Ser Pro
Trp Ser Pro Gln
Trp Ser Gln Pro
Trp Thr Asn Pro
Trp Thr Pro Asn
Tyr Ala Thr Tyr
Tyr Ala Tyr Thr
Tyr Phe Ser Thr
Tyr Phe Thr Ser
Tyr His Pro Thr
Tyr His Thr Pro
Tyr Pro His Thr
Tyr Pro Thr His
Tyr Ser Phe Thr
Tyr Ser Thr Phe
Tyr Thr Ala Tyr
Tyr Thr Phe Ser
Tyr Thr His Pro
Tyr Thr Pro His
Tyr Thr Ser Phe
Tyr Thr Tyr Ala
Tyr Tyr Ala Thr
Tyr Tyr Thr Ala
13,14-epoxy Fluprostenol Isopropyl Ester
europium(3+),1,2,3,5-tetramethylcyclopenta-1,3-diene
2-[(e)-3-(3,3-dimethyl-1-phenyl-1,3-dihydro-2h-indol-2-ylidene)-1-propenyl]-3,3-dimethyl-1-phenyl-3h-indolium chloride
D-glycero-D-gulo-Dec-1-enitol, 4,7-anhydro-1,2,3,8-tetradeoxy-6-O-(phenylmethyl)-, 9,10-dibenzoate
2-[(1S,3S,4aS,9aR)-1-(hydroxymethyl)-6-[(2-methoxy-1-oxoethyl)amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(4-phenylphenyl)methyl]acetamide
3-(2,5-difluorophenyl)-1-[[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-8-(3-methoxyprop-1-ynyl)-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methylurea
C26H30F2N4O5 (516.2184153999999)
3-(2,5-difluorophenyl)-1-[[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-8-(3-methoxyprop-1-ynyl)-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methylurea
C26H30F2N4O5 (516.2184153999999)
3-(2,5-difluorophenyl)-1-[[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-8-(3-methoxyprop-1-ynyl)-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methylurea
C26H30F2N4O5 (516.2184153999999)
N-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[4-(phenylmethyl)-1-piperidinyl]ethyl]-3-oxanyl]-4-methoxybenzenesulfonamide
3-(2,5-difluorophenyl)-1-[[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-8-(3-methoxyprop-1-ynyl)-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methylurea
C26H30F2N4O5 (516.2184153999999)
3-(2,5-difluorophenyl)-1-[[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-8-(3-methoxyprop-1-ynyl)-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methylurea
C26H30F2N4O5 (516.2184153999999)
3-(2,5-difluorophenyl)-1-[[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-8-(3-methoxyprop-1-ynyl)-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methylurea
C26H30F2N4O5 (516.2184153999999)
3-(2,5-difluorophenyl)-1-[[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-8-(3-methoxyprop-1-ynyl)-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methylurea
C26H30F2N4O5 (516.2184153999999)
3-(2,5-difluorophenyl)-1-[[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-8-(3-methoxyprop-1-ynyl)-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methylurea
C26H30F2N4O5 (516.2184153999999)
N-[(2S,3R,6R)-6-[2-(4-benzylpiperidin-1-yl)-2-oxoethyl]-2-(hydroxymethyl)oxan-3-yl]-4-methoxybenzenesulfonamide
N-[(2R,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[4-(phenylmethyl)-1-piperidinyl]ethyl]-3-oxanyl]-4-methoxybenzenesulfonamide
2-fluoro-N-[[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-(2-pyridin-4-ylethynyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylbenzamide
2-fluoro-N-[[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-(2-pyridin-4-ylethynyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylbenzamide
2-fluoro-N-[[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-(2-pyridin-4-ylethynyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylbenzamide
2-fluoro-N-[[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-(2-pyridin-4-ylethynyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylbenzamide
2-fluoro-N-[[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-(2-pyridin-4-ylethynyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylbenzamide
N-[(2R,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[4-(phenylmethyl)-1-piperidinyl]ethyl]-3-oxanyl]-4-methoxybenzenesulfonamide
N-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[4-(phenylmethyl)-1-piperidinyl]ethyl]-3-oxanyl]-4-methoxybenzenesulfonamide
2-[(1S,3R,4aS,9aR)-1-(hydroxymethyl)-6-[(2-methoxy-1-oxoethyl)amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(4-phenylphenyl)methyl]acetamide
2-[(1R,3S,4aS,9aR)-1-(hydroxymethyl)-6-[(2-methoxy-1-oxoethyl)amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(4-phenylphenyl)methyl]acetamide
2-fluoro-N-[[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-(2-pyridin-4-ylethynyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylbenzamide
2-fluoro-N-[[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-(2-pyridin-4-ylethynyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylbenzamide
2-fluoro-N-[[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-(2-pyridin-4-ylethynyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylbenzamide
N-[(2S,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[4-(phenylmethyl)-1-piperidinyl]ethyl]-3-oxanyl]-4-methoxybenzenesulfonamide
N-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[4-(phenylmethyl)-1-piperidinyl]ethyl]-3-oxanyl]-4-methoxybenzenesulfonamide
N-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[4-(phenylmethyl)-1-piperidinyl]ethyl]-3-oxanyl]-4-methoxybenzenesulfonamide
2-[(1R,3R,4aR,9aS)-1-(hydroxymethyl)-6-[(2-methoxy-1-oxoethyl)amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(4-phenylphenyl)methyl]acetamide
2-[(1R,3S,4aR,9aS)-1-(hydroxymethyl)-6-[(2-methoxy-1-oxoethyl)amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(4-phenylphenyl)methyl]acetamide
2-[(1R,3R,4aS,9aR)-1-(hydroxymethyl)-6-[(2-methoxy-1-oxoethyl)amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(4-phenylphenyl)methyl]acetamide
2-[(1S,3S,4aR,9aS)-1-(hydroxymethyl)-6-[(2-methoxy-1-oxoethyl)amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(4-phenylphenyl)methyl]acetamide
2-[(1S,3R,4aR,9aS)-1-(hydroxymethyl)-6-[(2-methoxy-1-oxoethyl)amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(4-phenylphenyl)methyl]acetamide
[2,4-dihydroxy-3-[(E)-3-methylbut-1-enyl]phenyl]-[6-(2,4-dihydroxyphenyl)-2-(2,6-dihydroxyphenyl)-4-methylcyclohex-3-en-1-yl]methanone
[2-Hydroxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropyl] dodecanoate
N-(3-aminopropyl)-N-[1-(3-benzyl-7-chloro-4-oxoquinazolin-2-yl)-2-methylpropyl]-4-methylbenzamide
C30H33ClN4O2 (516.2291908000001)
BI-2852
BI-2852 is a KRAS inhibitor for the switch I/II pocket (SI/II-pocket) by structure-based agent design with nanomolar affinity. BI-2852 is mechanistically distinct from covalent KRASG12C inhibitor (binds to switch II pocket) and binds ten-fold more strongly to active KRASG12D versus KRASwt (740 nM vs 7.5 μM). BI-2852 blocks GEF, GAP, and effector interactions with KRAS, leading to inhibition of downstream signaling and an antiproliferative effect in KRAS mutant cells.